

Man vs Nature: what the government can fix and what it can't (a quick read, mostly charts)


There are some things the government can try and fix during a pandemic and other things which it can't. All our coronavirus materials are updated daily [here](#). In this note, we highlight some of what we have posted recently, and which can be divided into issues the government can fix (credit availability and cost, income loss) and things it cannot (economic activity during a lockdown, the speed of medical advances).

- Trackers of high frequency US manufacturing and consumer data
- Trackers of the Fed's ability to reduce liquidity problems in credit markets, and where we see value
- A history of markets recovering before employment
- The Chloroquine controversy and the problem with non-randomized trials
- The limited value of infection prediction models (they usually don't work until you know the answer)

An early read on high frequency US manufacturing and consumer data

By now you've seen the extraordinary measures enacted by the Fed and the Congress. I will not enumerate them here, but they are both extensive and unprecedented. Instead, as investors, we're more interested in how successful they will be in combatting the surge in jobless claims that occurred last week. Our new tracking charts appear below and are critical to our understanding of the pandemic and its market, investment and economic consequences.

US jobless claims as % of active working population (employed + looking for work)




Source: Department of Labor, St. Louis Federal Reserve. March 26, 2020.

On the jobless claim number


A virus-led spike in jobless claims is not quite the same as a spike in jobless claims during a demand-led recession, given the speed with which unemployed people may go back to work once lockdown provisions are lifted, and given provisions in the \$2 trillion fiscal stimulus bill designed to incentivize companies to hire them back (in which case gov't loans could become grants)

US 2020 manufacturing tracker and daily infections



Source: WWPA, EIA, AISI, AAR, EEI, Haver. JPMAM. March 28, 2020.

US 2020 consumer tracker and daily infections




Source: Redbook Research, Johns Hopkins University. March 28, 2020.

A history of markets and unemployment


I don't know if the March 23 S&P 500 closing level of 2,237 will mark the low for this cycle, it may be too soon for that. When the bottom does occur, I expect it to be consistent with prior cycles in the US and Europe in which markets bottomed well before unemployment levels started to decline. Look at the stagflation era of the 1970's; equities bottomed when unemployment was just starting to *rise*. The tech collapse, in which peak unemployment closely coincided with the market bottom, was the exception.

1970's stagflation crisis




Source: Bloomberg, BLS. 2020.

1980's inflation / housing crisis




Source: Bloomberg, BLS. 2020.

Tech collapse




Source: Bloomberg, BLS. 2020.

Financial crisis




Source: Bloomberg, BLS. 2020.

UK equity market and unemployment rate in the 1970's



Source: Bloomberg, Federal Reserve Bank of St. Louis. 2020.

European equities and unemployment rate during global financial crisis, Index level



Source: STOXX, Eurostat. 2020.

Measuring the Fed’s ability to alleviate a credit and liquidity crunch

Over the next few weeks, the Fed will launch a variety of credit facilities designed to alleviate pressure in credit markets. The magnitude of spread increases are in many cases much smaller than in 2008, which reflects improvements in the plumbing and capitalization of the banking sector. **Note in the 6th chart how spreads for bank debt have barely budged relative to non-bank investment grade issuers.**

The new facilities include loans, asset purchases and relaxed accounting standards for banks, all of which are designed to reduce selling pressure and improve the flow and cost of credit. We expect the benefits to show up within weeks, particularly at the short end of the curve. We see value in investment grade credit, select municipal issuers and upper tier non-energy high yield. These charts are all in our online coronavirus portal and are updated frequently. Red dots indicate current levels.

3 month LIBOR - 3 month forward Fed Funds rate
basis points




Source: Bloomberg. March 27, 2020.

US 3 month Libor - 3 month Treasury (TED spread)
basis points




Source: Bloomberg. March 27, 2020.

US commercial paper - 3 month Treasury
basis points



Source: Bloomberg. March 26, 2020.

AAA asset backed securities spreads
basis points, spread versus Treasury



Source: J.P. Morgan. March 27, 2020.

US investment grade corporate bond spreads
JULI index spread versus Treasury, basis points



Source: Bloomberg, J.P. Morgan. March 27, 2020.

Financial - Non financial investment grade bond spreads
JULI index spread difference, basis points, banks vs non banks



Source: Bloomberg. March 27, 2020.

30 year fixed rate mortgage - 10 year Treasury

basis points



Source: Bloomberg, J.P. Morgan. March 27, 2020.

US high yield corporate bond spreads

JPDFHYI index spread versus Treasury, basis points



Source: Bloomberg, J.P. Morgan HY Team. March 27, 2020.

Fixed rate preferred securities option adjusted spread

POP1 index, basis points



Source: Bloomberg, J.P. Morgan. March 27, 2020.

Emerging markets dollar denominated bonds

Spread vs US Treasuries, basis points



Source: Bloomberg, J.P. Morgan. March 27, 2020.

S&P 500 leveraged loan price index

SPBDALB index



Source: Bloomberg. March 27, 2020.

Fed facilities

- Money market lending facility
- Fed purchases of US Treasuries
- Commercial paper funding facility for municipals
- Fed purchases of mortgage back securities
- Term asset backed securities loan facility
- Commercial paper funding facility for corporates
- Primary investment grade credit funding facility (direct lending)
- Secondary corporate credit funding facility (asset purchases)
- Fed lending to Exchange Stabilization Fund (Main Street lending fund)


The Chloroquine controversy

The development of anti-viral medications and vaccines is typically a lengthy and complex process involving randomized trials, control groups, large population sets and a variety of steps designed to demonstrate both efficacy and safety for broad public use. **Most anti-viral studies reported in the press so far and which are cited on the following pages meet few of these qualifications**, and have been conducted in “wartime” conditions in China and elsewhere posing great risk to doctors and other healthcare providers. While some of these drugs may eventually be used to combat the disease, it would be premature based on non-randomized trials of twenty or thirty people to draw concrete inferences about their effectiveness.

As a reminder of how complex anti-viral development can be, consider this: from 1963 to 2016, **of the thousands of anti-viral inhibitors proposed in scientific literature, only 90 were approved for final use**. Another reminder: numerous therapies were tested against Ebola, including chloroquine, favipiravir, brincidofovir, monoclonal antibodies, antisense RNA and convalescent plasma. Ultimately, none proved to be effective or safe as proven via randomized clinical trial.

History of antiviral drug development


Number of approved drugs




Source: De Clercq and Li, “Approved anti-viral drugs over the past 50 years”, Clinical Microbiology Reviews. June 2016.

Anti-virals and the Chloroquine controversy

Gilead’s **Remdesivir** and Bayer AG’s **Chloroquine** have reportedly shown promise in field tests to treat patients that have already contracted COVID-19, but there are some very important caveats to be aware of. Remdesivir and Chloroquine (a widely-used anti-malarial and autoimmune drug) reduced viral loads in cell cultures with low levels of toxicity to the cell. That’s what is shown in the next chart on the left; but remember, these are **cell cultures** and not live trials, there are no successful vaccines against *any* of the coronaviruses, and there are numerous drugs that were promising in vitro for other infectious diseases and **which failed in clinical studies**.



Source: Wuhan Institute of Virology. February 4, 2020.




Source: Gautret et al, IHU-Méditerranée Infection. March 2020.

The **controversy on Chloroquine** deepened with widespread media reports of positive results from a March study from France that combined chloroquine and azithromycin (a “Z-pack”). The chart above (right) made the rounds on the internet very quickly. **However**, it is now clear that this French study:

- was a non-randomized trial with only 36 patients, and had no discussion of outcomes
- excluded 6 recipients that were not discussed, some of whom required ventilation and/or died
- started out with higher viral loads in the control group than in the infected patients, which could explain why the control group showed higher infected rates at the conclusion of the study
- imputed more than 1/3 of the control group virus tests rather than measuring them
- sourced its treatment group (unlike the control group) from a single medical center

The Chloroquine outlook was muddled further by the Shanghai Public Health Clinical Center which found **no benefits at all** from Chloroquine when comparing the control group vs the treatment group:

Results of small 30-patient study using hydroxychloroquine for COVID-19, % of patients experiencing indicated result



Source: Chen Jun et al, Shanghai Public Health Clinical Center. March 2020.

All of these uncertainties led to strongly worded caveats in a paper published on March 30 in the American College of Physicians "Annals of Internal Medicine", which concluded as follows on the subject of hydroxychloroquine (HCQ):

"There is enough rationale to justify the continued investigation of the efficacy and safety of HCQ in hospitalized COVID-19 patients. It is critical to reiterate that while viral clearance is important, clinical outcomes are much more relevant to patients. **There currently are no data to recommend the use of HCQ as a prophylactic for COVID-19, although we eagerly await data from trials underway.** Thus, we discourage its off-label use until justified and supply is bolstered. The HCQ shortage will not only limit availability to COVID-19 infected patients if efficacy is truly established, but also represents a real risk to patients with rheumatic diseases who depend on HCQ for their survival."

Alfred Kim (Washington University School of Medicine) and Jeffrey Sparks (Harvard Medical School) in "Rush to Judgment"

Another example of unclear results: a study on Lopinavir-Ritonavir involving a randomized trial of 199 people in Wuhan. The 28-day mortality was 19.2% in the treatment group and 25.0% in the placebo group, which are not meaningfully different outcomes. Other anti-virals in clinical trials include the immunomodulator tocilizumab, which showed positive results in a small 20-patient study in China that Genentech is now expanding into a Phase III study under the brand name Actemra.

All things considered, we should probably all stop flocking to front-line studies of 20-50 patients. Single-group studies without concurrent controls are very unlikely to lead to any definitive conclusions on efficacy or safety; the results from **randomized clinical trials are the only viable path to an anti-viral solution:**

"With the current COVID-19 pandemic, randomized clinical trials have been launched around the world, including an adaptive trial sponsored by the NIH. This unprecedented speed from concept to implementation in just a few weeks is noteworthy and provides proof that clinical trials can be promptly initiated even in the middle of a pandemic."

Andre Kalil, University of Nebraska Medical Center

Sources used in this section

"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*", Nature Magazine, Zhihong Hu et al, February 4, 2020

"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial", Gautret et al, International Journal of Antimicrobial Agents, March 2020

"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19", Chen Jun et al, Shanghai Public Health Clinical Center/Fudan University, March 2020

"A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19", Alfred Kim (Washington University School of Medicine in St Louis) and Jeff Sparks (Harvard Medical School) in the American College of Physicians' "Annals of Internal Medicine", March 30 2020

"Treating COVID-19: Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics", Andre Kalil, University of Nebraska Medical Center, March 24, 2020

Why aren't we predicting infections for COVID-19? Because by the time the models actually work, you already know the answer [Warning: only for those of you who like math]

You might have seen infection prediction curves floating around for different countries. We have not found a lot of value in this exercise. The best way to explain why is with a model first applied to Korea in mid February, and then in vain to other countries¹.


Many epidemic outbreak models are based on the Kermack/McKendrick "SIR" model developed in the 1920's, which refers to "susceptible, infected and removed". The model estimates the number of active infections out of a given exposed population. Active infections rise based on new infections, and fall due to recoveries and mortalities. The three primary inputs are infectiousness (beta), removal rates (gamma) and the size of the exposed population as a % of the total population in a given region (Nper).

However, while this sounds very scientific, there's a lot of manual curve-fitting going on. One reason: it's hard to predict reported infections for a very infectious disease when large numbers of infected people are asymptomatic or for other reasons not reported, since the model will need to somehow reconcile fewer reported cases than it expects.

In any case, let's start with Korea. The first chart (left) shows how our model could have been applied to Korea in mid-February with a given set of assumptions. Looks great, right? Don't get too excited. While it worked for Korea, the calibrated parameters proved to be **completely useless** in forecasting infections for Italy. The second chart shows what mid-February Korea parameters would have predicted for Italy (peak active infections of 9,000), compared to what has *actually* happened (62,000 active infections so far). **This massive estimation failure is not hard to understand;** the Korea parameters were fit for a country whose policy and behavioral dynamics were completely different than Italy.

A good fit for Korea in mid-February


Active infections in Korea, thousands



Source: Johns Hopkins. J.P. Morgan Asset Management. March 26, 2020.

Korea parameters: a really, really bad fit for Italy

Active infections in Italy, thousands




Source: Johns Hopkins. J.P. Morgan Asset Management. March 26, 2020.

¹ My son Max, who will be attending the Harvard School for Applied Computational Science in the fall, helped with this section. My models are typically written in Excel's Visual Basic. He's dismissive of VBA, so I told him that I consider VBA the programming language of the gods. His response: "yes, but it would be the programming language of gods of a society that became extinct hundreds of years ago". If you were a computer science major, you would find this exchange to be hilarious. Max writes everything in Python.


After seeing how poorly the model performed for Italy, we could have waited a couple of weeks and recalibrated its parameters to fit Italy better, which is what the next chart shows on the left. Much better fit; however, we had to increase one of the parameters by a factor of 10x (!!). **And furthermore, what good is this tail-chasing exercise**, since (a) the revised calibration may well be useless for countries other than Italy, and (b) to make matters worse, **even this new recalibrated Italy curve could be completely wrong too** since there are other curves with more severe infection parameters that fit the actual Italy data just as well. That’s what is shown in the chart on the right; who’s to say which of these curves is the right one if they all fit the actual data so far??

The model, recalibrated for Italy: 10x higher infected population, Active infections in Italy, thousands



Source: Johns Hopkins. J.P. Morgan Asset Management. March 26, 2020.

Which set of assumptions best predicts Italy? Still totally unclear, Active infections in Italy, thousands



Source: Johns Hopkins. J.P. Morgan Asset Management. March 26, 2020.

The bottom line: infection prediction models must be constantly updated to fit the observed actual infection curve in each country². As a result, what you learn by fitting parameters for one country has practically no value in predicting the evolution of infections in any other country; and the predictions *within* any given country can shift wildly with the level of testing and policy changes. The best these models can do is provide a very rough estimate of potential infection trajectories for a single country assuming that public policy, testing and behaviors do not change over time, and even then, they could be totally wrong. These models are most accurate when infections are shown to have already peaked, at which point they become redundant.

² By the way, you don’t even need a fancy SIR model to fit infection curves; we replicated the Korean infection curve with similar precision by simply using a modified version of the formula $y = \exp(-x^2)$.

NOT FOR RETAIL DISTRIBUTION: This communication has been prepared exclusively for institutional, wholesale, professional clients and qualified investors only, as defined by local laws and regulations.

This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitutes Michael Cembalest's judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

This is a promotional document and is intended to report solely on investment strategies and opportunities identified by J.P. Morgan Asset Management and as such the views contained herein are not to be taken as a advice or a recommendation to buy or sell any investment or interest thereto. This document is confidential and intended only for the person or entity to which it has been provided. Reliance upon information in this material is at the sole discretion of the reader. The material was prepared without regard to specific objectives, financial situation or needs of any particular receiver. Any research in this document has been obtained and may have been acted upon by J.P. Morgan Asset Management for its own purpose. The results of such research are being made available as additional information and do not necessarily reflect the views of J.P. Morgan Asset Management. This presentation is qualified in its entirety by the offering memorandum, which should be carefully read prior to any investment in a fund. The purchase of shares of a fund is suitable only for sophisticated investors for whom an investment in such fund does not constitute a complete investment program and who fully understand and are willing to assume the risks involved in such fund's investment program. An investment in the funds involves a number of risks. For a description of the risk factors associated with an investment in a fund, please refer to the section discussing risk factors in the offering memorandum (available upon request). Shares of the funds are not deposits, obligations of, or endorsed or guaranteed by, JPMorgan Chase Bank, NA or any other bank and are not insured by the FDIC, the Federal Reserve Board or any other government agency. Any forecasts, figures, opinions, statements of financial market trends or investment techniques and strategies expressed are those of J.P. Morgan Asset Management, unless otherwise stated, as of the date of issuance. They are considered to be reliable at the time of production, but no warranty as to the accuracy and reliability or completeness in respect of any error or omission is accepted, and may be subject to change without reference or notification to you. Investments in Alternative Investment Funds (AIFs) involves a high degree of risks, including the possible loss of the original amount invested. The value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements. Changes in exchange rates may have an adverse effect on the value, price or income of the products or underlying investment. Both past performance and yields are not reliable indicators of current and future results. There is no guarantee that any forecast will come to pass. Any investment decision should be based solely on the basis of any applicable local offering documents such as the prospectus, annual report, semi-annual report, private placement or offering memorandum. For further information, any questions and for copies of the offering material you can contact your usual J.P. Morgan Asset Management representative. Any reproduction, retransmission, dissemination or other unauthorized use of this document or the information contained herein by any person or entity without the express prior written consent of J.P. Morgan Asset Management is strictly prohibited.

J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at <https://am.jpmorgan.com/global/privacy>

This communication is issued by the following entities:

In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients' use only, by local J.P. Morgan entities, as the case may be.; in Canada, for institutional clients' use only, by JPMorgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by JPMorgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority; in other European jurisdictions, by JPMorgan Asset Management (Europe) S.à r.l. In Asia Pacific ("APAC"), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated: JPMorgan Asset Management (Asia Pacific) Limited, or JPMorgan Funds (Asia) Limited, or JPMorgan Asset Management Real Assets (Asia) Limited, each of which is regulated by the Securities and Futures Commission of Hong Kong; JPMorgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; JPMorgan Asset Management (Taiwan) Limited; JPMorgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number "Kanto Local Finance Bureau (Financial Instruments Firm) No. 330"); in Australia, to wholesale clients only as defined in section 761A and 761G of the Corporations Act 2001 (Commonwealth), by JPMorgan Asset Management (Australia) Limited (ABN 55143832080) (AFSL 376919).

Copyright 2020 JPMorgan Chase & Co. All rights reserved.